4TEEN4 Pharmaceuticals

4TEEN4 Pharmaceuticals GmbH is a biotechnology company focused on developing innovative treatments for Cardiogenic Shock, a severe condition with high mortality rates primarily affecting patients in intensive care units. The company's flagship product, Procizumab, is a first-in-class inhibitor of the Dipeptidyl Peptidase 3 (DPP3) pathway, designed to restore cardiac function and reduce mortality. Procizumab has shown clinical proof of concept and represents a breakthrough in an area with no effective therapies currently available.

4TEEN4 Pharmaceuticals operates in the healthcare and pharmaceutical markets, targeting hospitals and medical institutions that treat acute myocardial injuries and related conditions. The company generates revenue through the development and potential commercialization of its proprietary drug, Procizumab.

Supported by funding from the European Social Fund (ESF) and the Federal State of Brandenburg, 4TEEN4 Pharmaceuticals is committed to advancing medical science and improving patient outcomes. The company employs a team of dedicated scientists and innovators, working in a dynamic small-to-medium enterprise (SME) environment.

Keywords: Cardiogenic Shock, Procizumab, DPP3 inhibitor, biotechnology, clinical proof, cardiac function, high mortality, intensive care, myocardial injuries, pharmaceutical innovation.